imb-1018972
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Mar 21, 2020 (NCT04306237)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Estradiol 17-beta-dehydrogenase 12INHIBITOR
HSD17B12 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(CN2CCN(CCOC(=O)c3cccnc3)CC2)c(OC)c1OC- Mol. weight
- 415.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095242 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07023614 | Phase 2 | Oct 6, 2025 | Imbria Pharmaceuticals |
| NCT04826185 | Phase 2 | Jun 14, 2021 | Imbria Pharmaceuticals |
| NCT04826172 | Phase 2 | Apr 23, 2021 | Imbria Pharmaceuticals |
| NCT04826159 | Phase 2 | Apr 21, 2021 | Imbria Pharmaceuticals, University of Oxford |
| NCT04306237 | Phase 2 | Mar 21, 2020 | Imbria Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imbria Pharmaceuticals | For profit | 5 | 5 | 1 | 2020 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1